Completed PHASE3 INTERVENTIONAL 3-arm NCT00003937

Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma

Protocol for Patients With Newly-Diagnosed Non-Metastatic Osteosarcoma - A POG/CCG Pilot Intergroup Study

Sponsor: Children's Oncology Group

Interventions cisplatin conventional surgery dexrazoxane hydrochloride doxorubicin hydrochloride etoposide ifosfamide methotrexate

Updated 6 times since 2017 Last updated: Aug 4, 2014 Started: Sep 30, 1999 Primary completion: Mar 31, 2004 Completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Cardiac Toxicity and Sarcoma, this trial is completed. The trial is conducted by Children's Oncology Group and has accumulated 6 data snapshots since 1999. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Oncology Group
National Cancer Institute (NCI)

Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Ann Arbor, United States , Asheville, United States , Atlanta, United States , Baltimore, United States , Bangor, United States , Bern, Switzerland , Birmingham, United States , Boston, United States , Buffalo, United States and 100 more locations